Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes

{
  "id": "MLC-T-ONC-010378",
  "term": "Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "Autologous activated T-cells that have been coated with bispecific antibodies (BiAb) comprised of an anti-CD3 monoclonal antibody heteroconjugated to an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, with potential antineoplastic and immunomodulating activities. Upon administration, anti-CD3 x anti-EGFR bispecific antibody-armed activated T-cells (AATC) attach to and selectively cross-link CD3-expressing T-cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. In addition, cytokine and chemokine secretion by the T-cells further activates the immune system, which leads to the recruitment and activation of CTLs, and additional CTL-mediated tumor-specific cell lysis. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells, and is required for signal transduction. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.",
  "synonyms": [
    "anti-CD3 x anti-EGFR AATCs",
    "anti-CD3 x anti-EGFR BATs",
    "anti-CD3 x anti-EGFR-bispecific antibody armed activated autologous T cells",
    "Anti-CD3 x Anti-EGFR-bispecific Antibody Armed Activated Autologous T-cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd3-anti-egfr-bispecific-monoclonal-antibody-armed-activated-autologous-t/"
}